Acadia, page-45

But note the last sentence:

Goldman Sachs analyst Salveen Richter downgraded Acadia Pharmaceuticals to Sell from Neutral with a price target of $12, down from $15. The company's Q3 Nuplazid revenue was below consensus, and it faces a challenging forward outlook due to unfavorable channel dynamics and pricing constraints due to the recently passed Inflation Reduction Act which has historically been a key lever for Nuplazid sales growth, the analyst tells investors in a research note. Richter adds however that she continues to monitor Acadia's pipeline and sees a potentially notable opportunity for trofinetide in Rett syndrom.